Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic Review

• Published in: Journal of Evidence-Based Complementary & Alternative Medicine 2017-10, Vol.22 (4), p.956-968
• Main Authors: Koppen, Laura M., Whitaker, Andrea, Rosene, Audrey, Beckett, Robert D.
• Format: Article
• Language: English
• Subjects: Berberine - administration & dosage; Berberine - therapeutic use; Biological Products - administration & dosage; Clinical research; Clinical trials; Clinical Trials as Topic; Density; Drug Therapy, Combination; Efficacy; Evidence-based medicine; Ezetimibe - therapeutic use; Female; Humans; Hyperlipidemia; Hyperlipidemias - blood; Hyperlipidemias - drug therapy; Lipids - blood; Male; Metabolic disorders; Statins; Systematic review; Topical Review; Transparency; Triglycerides
• ISSN: 2156-5872; 2156-5899; 2515-690X
• DOI: 10.1177/2156587216687695

The objective of this review is to identify, summarize, and evaluate clinical trials of berberine for the treatment of hyperlipidemia and other dyslipidemias. A literature search for randomized, controlled trials of berberine that assessed at least 2 lipid values as endpoints resulted in identification of 12 articles that met criteria. The majority of evaluated articles consistently suggest that berberine has a beneficial effect on low-density lipoprotein (reductions ranging from approximately 20 to 50 mg/dL) and triglycerides (reductions ranging from approximately 25 to 55 mg/dL). Common study limitations included lack of reporting of precision in their endpoints, description of blinding, transparency in flow of patients, and reporting of baseline concomitant medications. Berberine could serve as an alternative for patients who are intolerant to statins, patients resistant to starting statin therapy but who are open to alternative treatments, and for low-risk patients not indicated for statin therapy.